BAJAJHCARE Stock Overview
A pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 2/6 |
Bajaj HealthCare Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹391.50 |
52 Week High | ₹428.50 |
52 Week Low | ₹263.30 |
Beta | 0.58 |
11 Month Change | 15.01% |
3 Month Change | -4.56% |
1 Year Change | 3.42% |
33 Year Change | 7.67% |
5 Year Change | n/a |
Change since IPO | 7.87% |
Recent News & Updates
Recent updates
Bajaj HealthCare's (NSE:BAJAJHCARE) Dividend Will Be ₹1.00
Sep 12Bajaj HealthCare Limited (NSE:BAJAJHCARE) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Jul 12Bajaj HealthCare (NSE:BAJAJHCARE) Has Announced That Its Dividend Will Be Reduced To ₹1.00
Sep 10We Think That There Are More Issues For Bajaj HealthCare (NSE:BAJAJHCARE) Than Just Sluggish Earnings
Nov 19Bajaj HealthCare Limited (NSE:BAJAJHCARE) Soars 30% But It's A Story Of Risk Vs Reward
Jan 17Shareholder Returns
BAJAJHCARE | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | 0.1% | 0.5% | 0.5% |
1Y | 3.4% | 42.5% | 27.5% |
Return vs Industry: BAJAJHCARE underperformed the Indian Pharmaceuticals industry which returned 42.5% over the past year.
Return vs Market: BAJAJHCARE underperformed the Indian Market which returned 27.5% over the past year.
Price Volatility
BAJAJHCARE volatility | |
---|---|
BAJAJHCARE Average Weekly Movement | 5.6% |
Pharmaceuticals Industry Average Movement | 6.0% |
Market Average Movement | 6.1% |
10% most volatile stocks in IN Market | 9.1% |
10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: BAJAJHCARE has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: BAJAJHCARE's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 1,049 | Sajankumar Bajaj | www.bajajhealth.com |
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, venous disease, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It provides intermediates, such as guanine, 3-methyl xanthine, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid, ticagrelor acetonide, 4,7-dichloroquinolone, 5-[N-ethyl-N-(2-hydroxyethyl)amino]-2-aminopentane, 2-amino -4-hydroxyacetophenone, 8- chloro theophylline, 8 bromo-3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine, (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile, 3 – amino – 1 – adamantanol, N – boc -sitagliptin, sitagliptin base, hesperidine, (2,7-dichlori-9H-fluorene), (2-Chloro-1-(2,7- dichlori-9H-fluoren-4-yl)ethanone), (2-(dibutylamino)-1-(2, 7- dichlori-9H-fluoren-4-yl)ethanol), (2-Nitro-4-thiocyanoaniline), 4- (propylthio) benzene -1,2-diamine, methyl [(E)amino(methylsulfanyl)methylidene] carbamate, and (2-phenoxy methane sulphonamide).
Bajaj HealthCare Limited Fundamentals Summary
BAJAJHCARE fundamental statistics | |
---|---|
Market cap | ₹12.36b |
Earnings (TTM) | -₹133.27m |
Revenue (TTM) | ₹4.76b |
2.6x
P/S Ratio-92.8x
P/E RatioIs BAJAJHCARE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BAJAJHCARE income statement (TTM) | |
---|---|
Revenue | ₹4.76b |
Cost of Revenue | ₹2.45b |
Gross Profit | ₹2.31b |
Other Expenses | ₹2.44b |
Earnings | -₹133.27m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -4.22 |
Gross Margin | 48.43% |
Net Profit Margin | -2.80% |
Debt/Equity Ratio | 119.6% |
How did BAJAJHCARE perform over the long term?
See historical performance and comparison